The Latest Breaking News from Johnson & Johnson (

On July 8, US President Donald Trump shook the biopharmaceutical sector by announcing a tariff of up to 200% on pharmaceuticals, which would take effect “very soon.” 80% of prescription drugs sold in the US are made abroad, a statistic the President wants to flip on its head.

These blue-chip stocks offer a rare combination of stability, resilience, and moderate growth.

With solid Q2 results and 2025 guidance increases, Wall Street is upgrading these four stocks. Analysts now see palpable upside in one streaming stalwart.

Ever feel like you’re making diverse choices at the grocery store or pharmacy? In reality, many of the brands you think are competitors are actually owned by the same parent company. These corporate giants dominate entire industries, using multiple brand identities to give the illusion of variety. Once you understand…

Johnson Johnson (NYSE:JNJ) stalled out at resistance around the $165 level. There tends to be resistance at price levels that had previously been resistance. As you can see on the chart below, that's the case here. This level was also resistance in March.

Three dividend stocks stand out in July, offering reliable income, attractive yields, and strong fundamentals to help investors navigate market volatility

U.S. stocks moved higher today, with the Dow Jones gaining more than 200 points, or 0.5%, to close at 44,254.78. The Nasdaq added 0.25% to finish at 20,730.49, while the SP 500 advanced 0.3% to 6,263.70.

Johnson & Johnson is back in rally mode after years of post-pandemic normalization and the impact of repositioning, set up to sustain higher prices for years.

U.S. stocks were slightly lower, with the Dow Jones index falling around 0.1% on Wednesday.

Johnson & Johnson stock jumped Wednesday after the Dow health behemoth raised its guidance in the wake of a bullish second-quarter report.

Johnson Johnson (NYSE:JNJ) on Wednesday reported a second-quarter 2025 adjusted earnings of $2.77 per share, down 1.8% year over year, beating the consensus of $2.68.